Stem Cell and Regenerative Medicine Center, University of Wisconsin-Madison, 1111 Highland Avenue, Wisconsin 53705, USA.
Nat Rev Drug Discov. 2010 May;9(5):367-72. doi: 10.1038/nrd3000. Epub 2010 Mar 26.
High-throughput screening technologies are widely used in the early stages of drug discovery to rapidly evaluate the properties of thousands of compounds. However, they generally rely on testing compound libraries on highly proliferative immortalized or cancerous cell lines, which do not necessarily provide an accurate indication of the effects of compounds in normal human cells or the specific cell type under study. Recent advances in stem cell technology have the potential to allow production of a virtually limitless supply of normal human cells that can be differentiated into any specific cell type. Moreover, using induced pluripotent stem cell technology, they can also be generated from patients with specific disease traits, enabling more relevant modelling and drug screens. This article discusses the opportunities and challenges for the use of stem cells in drug screening with a focus on induced pluripotent stem cells.
高通量筛选技术在药物发现的早期阶段被广泛应用,可快速评估数千种化合物的特性。然而,它们通常依赖于在高度增殖的永生化或癌细胞系上测试化合物文库,这并不一定能准确反映化合物在正常人类细胞或特定研究细胞类型中的作用。最近干细胞技术的进步有可能使人们能够生产出几乎无限数量的正常人类细胞,这些细胞可以分化成任何特定的细胞类型。此外,利用诱导多能干细胞技术,也可以从具有特定疾病特征的患者中生成,从而实现更相关的建模和药物筛选。本文讨论了利用干细胞进行药物筛选的机会和挑战,重点介绍诱导多能干细胞。